Strategic partnering is integral to our mission to develop innovative small molecule therapies that transform the treatment of cancer and other serious diseases. We are passionate about developing novel breakthrough medicines for patients with significant unmet medical needs. We believe that strategic collaborations complement our drug development efforts and are critical to help us achieve this goal.
We aim to partner with pharmaceutical companies, academic research organizations, and cancer research centers that are interested in developing small molecule therapies. This can be achieved either through direct collaboration on our in-house programs, enabling access to our drug discovery platform and expertise, or by licensing one of our development programs.
Partnering with Global Pharmaceutical Leaders
Through our high-value partnerships with leading global pharmaceutical companies including Novartis, Alexion, Genentech, Boehringer Ingelheim, Pfizer and Bristol-Myers Squibb, we have demonstrated success against some of the most challenging disease targets in multiple therapeutic areas using our proprietary drug discovery platform. If you are interested in discussing collaborative opportunities, please send an email to firstname.lastname@example.org.